Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIZATRIPTAN RPD | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2020-07-06 | 490 |
| APO-RIZATRIPTAN RPD | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2018-09-11 | 493 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-03-12 | 2017-03-31 | 725 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-04-24 | 2017-06-13 | 7716 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-05-02 | 2017-08-16 | 8710 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-05-02 | 2017-08-17 | 8713 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-06-13 | 2024-07-05 | 230492 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-11-15 | 2025-02-14 | 243190 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2021-04-30 | 2021-05-25 | 138355 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2024-01-12 | 2024-02-09 | 215979 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2022-03-25 | 2022-04-11 | 157329 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2022-04-08 | 2022-04-22 | 158370 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-12-18 | 2020-03-09 | 101517 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2022-12-16 | 2023-01-06 | 178763 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-03-23 | 2023-04-27 | 187730 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-04-27 | 2023-05-06 | 190865 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-05-19 | 2023-06-16 | 192812 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2023-08-12 | 2023-08-23 | 201710 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-08-23 | 2023-09-01 | 202827 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-06-28 | 2017-10-03 | 14223 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |